Tesamorelin + Ipamorelin Blend Mechanism of Action
How Tesamorelin + Ipamorelin Blend works: receptor targets, signalling pathways, and molecular profile.
GHRH Analog + Selective Ghrelin Agonist
Tesamorelin is a GHRH analog that stimulates the pituitary's own GHRH receptor to release growth hormone in a physiological, pulsatile pattern — it's the only FDA-approved compound in this combination, approved as Egrifta for HIV-associated lipodystrophy. Ipamorelin works through a separate receptor, the ghrelin receptor, triggering an independent GH pulse. Hitting both receptors at once is the same combined-mechanism logic behind REGEN's existing CJC-1295 (no-DAC) + Ipamorelin blend, substituting Tesamorelin as the GHRH-analog half.
Why Pair a GHRH Analog with a Ghrelin Agonist
Because GHRH and ghrelin signal through distinct pituitary receptor pathways, combining an analog of each produces a larger GH pulse than either alone — a well-established pharmacological principle in GH secretagogue research, though it doesn't guarantee proportionally larger downstream benefits without dedicated combination-trial data.